clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Lung Neoplasms D008175 171 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Yamashita N et al. Effects of antibacterial agents, levofloxacin and clarithromycin, on aquatic organisms. 2006 Water Sci. Technol. pmid:16862775
Sahar E et al. Comparison of two treatments for the removal of selected organic micropollutants and bulk organic matter: conventional activated sludge followed by ultrafiltration versus membrane bioreactor. 2011 Water Sci. Technol. pmid:21330721
Lin AY et al. Fate of selected pharmaceuticals and personal care products after secondary wastewater treatment processes in Taiwan. 2010 Water Sci. Technol. pmid:21076233
Ghosh GC et al. Occurrence and elimination of antibiotics at four sewage treatment plants in Japan and their effects on bacterial ammonia oxidation. 2009 Water Sci. Technol. pmid:19237773
Harada A et al. Biological effects of PPCPs on aquatic lives and evaluation of river waters affected by different wastewater treatment levels. 2008 Water Sci. Technol. pmid:19001705
Nakada N et al. Occurrence of 70 pharmaceutical and personal care products in Tone River basin in Japan. 2007 Water Sci. Technol. pmid:18075189
Sein MM et al. Oxidation of some typical wastewater contaminants (tributyltin, clarithromycin, metoprolol and diclofenac) by ozone. 2009 Water Sci. Technol. pmid:19403960
Nakada N et al. Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant. 2007 Water Res. pmid:17632207
Abegglen C et al. The fate of selected micropollutants in a single-house MBR. 2009 Water Res. pmid:19269669
Vione D et al. Phototransformation of selected human-used macrolides in surface water: kinetics, model predictions and degradation pathways. 2009 Water Res. pmid:19249811
Wang S et al. Enhanced adsorption of ionizable antibiotics on activated carbon fiber under electrochemical assistance in continuous-flow modes. 2018 Water Res. pmid:29426033
Siemens J et al. Concentrations and mobility of human pharmaceuticals in the world's largest wastewater irrigation system, Mexico City-Mezquital Valley. 2008 Water Res. pmid:18083208
Forrez I et al. Biogenic metals for the oxidative and reductive removal of pharmaceuticals, biocides and iodinated contrast media in a polishing membrane bioreactor. 2011 Water Res. pmid:21163512
Yazdanbakhsh AR et al. Reduction of non-Betalactam Antibiotics COD by Combined Coagulation and Advanced Oxidation Processes. 2016 Water Environ. Res. pmid:28661328
Vichev E et al. [Gastroduodenitis and ulcers--statistical study for 1998]. 2000 Vutr Boles pmid:11688321
Starostin BD [Modern means of anti-Helicobacter therapy]. 2001 Voen Med Zh pmid:11764485
Díte P et al. [Double blind randomized multicentre study of a seven-day eradication regime of Helicobacter pylori by omeprazole, clarithromycin and ornidazole vs. omeprazole, clarithromycin and metronidazole]. 2002 Vnitr Lek pmid:16737149
Sandri A et al. Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice. 2018 Virulence pmid:29938577
Morgene MF et al. HaCaT epithelial cells as an innovative novel model of rhinovirus infection and impact of clarithromycin treatment on infection kinetics. 2018 Virology pmid:30077071
Zarogoulidis P et al. Long-term respiratory follow-up of H1N1 infection. 2011 Virol. J. pmid:21702977
Ebnöther M et al. Severe bronchiolitis in acute Mycoplasma pneumoniae infection. 2001 Virchows Arch. pmid:11787856
de Mascarel A et al. Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue. 2005 Virchows Arch. pmid:15742170
Bruhn O et al. Antimicrobial peptides and proteins of the horse--insights into a well-armed organism. 2011 Vet. Res. pmid:21888650
Clark SE et al. Identification of a multidrug efflux pump in Flavobacterium johnsoniae. Vet. Res. pmid:19558960
Sieber-Ruckstuhl NS et al. Long-term cure of disseminated Mycobacterium avium infection in a cat. 2007 Vet. Rec. pmid:17259458
Cattoli G et al. Helicobacter acinonychis eradication leading to the resolution of gastric lesions in tigers. 2000 Vet. Rec. pmid:10975334
Berghaus LJ et al. Mutant prevention concentration and mutant selection window for 10 antimicrobial agents against Rhodococcus equi. 2013 Vet. Microbiol. pmid:23915992
Hartmann FA et al. Molecular characterization of Staphylococcus intermedius carriage by healthy dogs and comparison of antimicrobial susceptibility patterns to isolates from dogs with pyoderma. 2005 Vet. Microbiol. pmid:15917140
Burton AJ et al. Efficacy of liposomal gentamicin against Rhodococcus equi in a mouse infection model and colocalization with R. equi in equine alveolar macrophages. 2015 Vet. Microbiol. pmid:25666452
Giguère S et al. In vitro synergy, pharmacodynamics, and postantibiotic effect of 11 antimicrobial agents against Rhodococcus equi. 2012 Vet. Microbiol. pmid:22704561
Hung SW et al. Antibiotic susceptibility and prevalence of erythromycin ribosomal methylase gene, erm(B) in Streptococcus spp. 2008 Vet. J. pmid:17400007
Sharman MJ et al. Gastrokine mRNA expression in gastric tissue from dogs with helicobacter colonisation but without inflammatory change during treatment. 2017 Vet. Immunol. Immunopathol. pmid:28494926
Giguère S Treatment of Infections Caused by Rhodococcus equi. 2017 Vet. Clin. North Am. Equine Pract. pmid:28161038
Muller MG et al. Acinetobacter baumannii in Localised Cutaneous Mycobacteriosis in Falcons. 2010 Vet Med Int pmid:20871867
Weese JS et al. Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: antimicrobial guidelines working group of the international society for companion animal infectious diseases. 2011 Vet Med Int pmid:21776346
Dhama K et al. Tuberculosis in Birds: Insights into the Mycobacterium avium Infections. 2011 Vet Med Int pmid:21776352
Rebuelto M and Loza ME Antibiotic Treatment of Dogs and Cats during Pregnancy. 2010 Vet Med Int pmid:21253497
Murai A et al. Mastitis caused by Mycobacterium kansasii infection in a dog. 2013 Vet Clin Pathol pmid:23808608
Hylton PK et al. Intracellular success: cytologic findings in an ulcerated submandibular mass from a cat. 2006 Vet Clin Pathol pmid:16967424
[Experience with treatment of chronic polypoid rhinosinusitis using low doses of clarithromycin in the postoperative period]. 2012 Vestn. Otorinolaringol. pmid:22678641
Bobacheva TIu [The treatment of chronic polypous rhinosinusitis in the postoperative period with low doses of clarithromycin]. 2012 Vestn. Otorinolaringol. pmid:23011378
Robinson JG Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. 2009 Vasc Health Risk Manag pmid:19436666
Kones R Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. 2010 Vasc Health Risk Manag pmid:20859545
Bronander KA and Bloch MJ Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data. 2007 Vasc Health Risk Manag pmid:17580728
Wolbrette D et al. Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy. 2010 Vasc Health Risk Manag pmid:20730068
Falk JA et al. The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. 2010 Vasc Health Risk Manag pmid:20479949
Edmonds M The treatment of diabetic foot infections: focus on ertapenem. 2009 Vasc Health Risk Manag pmid:19997576
Laks T et al. Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study. 2008 Vasc Health Risk Manag pmid:19337553
Lee CK et al. Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. 1999 Vaccine pmid:10195786
Rendi-Wagner P et al. National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases. 2009 Vaccine pmid:19393711